Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)

Monika M Kutyna, MSc, Amilia Wee, BSc (Hons), Sharon Paton, BSc, Dimitrios Cakouros, PhD, Agnes Arthur, PhD, Rakchha Chhetri, MBBS, Deepak Singhal, MBBS, MD FRACP, FRCPA, Stan Gronthos, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 1694.

https://doi.org/10.1182/blood-2019-126457

Published: 2019

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

Journal Articles

Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome

Blood (2018) 132 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2018-99-115828

Published: 2018

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome

Eiju Negoro, MD, PhD, Michael Clemente, M.S., Naoko Hosono, MD,PhD, Aziz Nazha, MD, Wenyi Shen, MD, Yasunobu Nagata, MD, PhD, Cassandra M. Hirsch, BSc, Bartlomiej P Przychodzen, MSc, Reda Z. Mahfouz, MD, PhD, Teodora Kuzmanovic, BSc, Hideki Makishima, MD PhD FACP., Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD, PhD, FACP

Blood (2016) 128 (22): 4290.

https://doi.org/10.1182/blood.V128.22.4290.4290

Published: 2016

Journal Articles

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, Amy E. DeZern, MD MHS, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A van de Loosdrecht, MD PhD, Arjan A van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, MD, Dolors Costa, Aristoteles Giagounidis, MD PhD, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, Maria Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, Detlef Haase, MD, Ana Africa Martin, Claudia D Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD MSc, Brayan Merchan, MD, Claudia Mende, María Teresa Ardanaz, MD, Christina Ganster, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Nomdedeu Benet, Peter L. Greenberg, MD, Ulrich Germing, MD, Guillermo Sanz, MD PhD

Blood (2015) 126 (23): 609.

https://doi.org/10.1182/blood.V126.23.609.609

Published: 2015

Journal Articles

Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA)

Eiju Negoro, MD PhD, Naoko Hosono, MDPhD, Wenyi Shen, MD, Tetsuichi Yoshizato, MD, Bhumika J. Patel, Cassandra Hirsh, BSc, Bartlomiej Przychodzen, MSc, Michael J. Clemente, Reda Z. Mahfouz, MDPhD, Aleksandra Wodnar-Filipowicz, PhD, Hideki Makishima, MD PhD, Seishi Ogawa, MD PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2015) 126 (23): 1652.

https://doi.org/10.1182/blood.V126.23.1652.1652

Published: 2015

Journal Articles

Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry

Mikkael A. Sekeres, MD, MS, Mohit Narang, MD, Rami S. Komrokji, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Alan F. List, MD, Thomas K. Street, R.Ph, MBA, Arlene S. Swern, PhD, Kristen A. Sullivan, MBA, David L. Grinblatt, MD

Blood (2010) 116 (21): 2931.

https://doi.org/10.1182/blood.V116.21.2931.2931

Published: 2010

Journal Articles

Secondary Myelodysplastic Syndrome.(sMDS) Presentation and Evolution.

Laura Kornblihtt, Alicia Enrico, Jorge Milone, Maria Virginia Prates, Carolina B Belli, Jorge Arbelbide, Diana Lafalce, MD, Diana Penchasky, MD, Dorotea Fantl, MD, Maria Marta Rivas, MS, PhD, Maria Cabrejo, Maria Caicedo

Blood (2009) 114 (22): 4850.

https://doi.org/10.1182/blood.V114.22.4850.4850

Published: 2009

Journal Articles

Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML).

Andrea Kuendgen, MD, Claudia Mende, MD, Detlef Haase, MD, Stephanie Fischer, MD, Barbara Hildebrandt, PhD, Aristoteles Giagounidis, MD, Rainer Haas, MD, Norbert Gattermann, MD, Ulrich Germing, MD

Blood (2007) 110 (11): 2451.

https://doi.org/10.1182/blood.V110.11.2451.2451

Published: 2007

NARROW

Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Clonal Events of Aplastic Anemia Related to the Evolution to Myelodysplastic Syndrome

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome (MDS)-Determining Clonal Events at Presentation of Aplastic Anemia (AA)

Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry

Secondary Myelodysplastic Syndrome.(sMDS) Presentation and Evolution.

Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only